Table 1 Baseline characteristics of primary prevention patients experienced VA vs. no VA
Baseline characteristics | Patients experienced VA(n = 210) | Patients not experienced VA (n = 261) | P-value |
|---|---|---|---|
Male | 166 (79.0%) | 193 (73.9%) | 0.231 |
Age(years) | 62.72 ± 11.83 | 61.50 ± 13.77 | 0.475 |
Ischemic heart disease | 57 (27.1%) | 48 (18.4%) | 0.023 |
Hypertension | 70 (33.3%) | 97 (37.2%) | 0.438 |
Diabetes | 28 (13.3%) | 27 (10.3%) | 0.317 |
Stroke | 4 (1.9%) | 6 (2.3%) | 1.000 |
Atrial fibrillation | 26 (12.4%) | 18 (6.9%) | 0.055 |
LVEF (%) | 33.13 ± 10.64 | 34.29 ± 9.48 | 0.218 |
LVEDD (mm) | 64.68 ± 12.94 | 63.48 ± 11.40 | 0.575 |
NYHA class III-IV | 129 (61.4%) | 169 (64.8%) | 0.457 |
Beta-blockers | 129 (61.4%) | 145 (55.6%) | 0.222 |
ACEI/ARB | 88 (43.8%) | 113 (43.3%) | 0.852 |
Diuretics | 77 (36.7%) | 102 (39.1%) | 0.633 |
Amiodarone | 47 (22.4%) | 47 (18.0%) | 0.248 |